Published in Endocr Rev on December 09, 2015
A Clinical Trial to Prevent New Onset Diabetes After Transplantation (ITP-NODAT) | NCT01683331
Vitamin D and Type 2 Diabetes Study (D2d) | NCT01942694
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant | NCT01928199
Genetic factors in pathogenesis of diabetes mellitus after kidney transplantation. Ther Clin Risk Manag (2017) 0.75
Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient. Drugs Aging (2017) 0.75
Inflammation and metabolic disorders. Nature (2006) 33.33
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet (2006) 11.64
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet (2008) 9.03
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Metformin: an update. Ann Intern Med (2002) 5.62
Diabetes mellitus after kidney transplantation in the United States. Am J Transplant (2003) 4.39
(2) Classification and diagnosis of diabetes. Diabetes Care (2015) 4.29
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care (2015) 3.80
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem (2001) 3.19
SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab (2015) 3.11
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int (2009) 2.72
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes (2008) 2.64
Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol (2008) 2.59
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 2.46
The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation (1987) 2.40
Posttransplantation diabetes: a systematic review of the literature. Diabetes Care (2002) 2.39
(8) Cardiovascular disease and risk management. Diabetes Care (2015) 2.31
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant (2003) 2.22
The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes (2007) 2.09
Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant (2006) 2.01
Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care (2013) 1.95
Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol (2004) 1.93
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant (2011) 1.90
Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol (2007) 1.90
Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation (2009) 1.79
Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int (2002) 1.76
New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int (2005) 1.73
Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis (2010) 1.65
Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. Liver Transpl (2007) 1.64
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant (2009) 1.63
Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant (2009) 1.60
Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant (2011) 1.59
Hepatitis C virus and liver transplantation. Clin Liver Dis (2006) 1.58
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int (2006) 1.57
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
(6) Glycemic targets. Diabetes Care (2015) 1.49
The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int (2014) 1.48
The renal metabolism of insulin. Diabetologia (1984) 1.48
Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation (2008) 1.46
(7) Approaches to glycemic treatment. Diabetes Care (2015) 1.46
Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int (2001) 1.45
Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol (2012) 1.44
New-onset diabetes after liver transplantation and its impact on complications and patient survival. J Diabetes (2015) 1.41
Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41
Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation (2001) 1.38
The natural history of recurrent hepatitis C and what influences this. Liver Transpl (2008) 1.38
Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 1.38
Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation (1999) 1.35
Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin Chem (2012) 1.33
Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation (2007) 1.26
Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation (1998) 1.26
Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes (2003) 1.25
Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. Transplantation (1991) 1.24
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant (2004) 1.23
Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol (2008) 1.23
Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol (2012) 1.22
Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation (2006) 1.22
Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab (2012) 1.20
Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol (2009) 1.16
Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol (2002) 1.16
Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia (2004) 1.15
Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant (2008) 1.13
Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl (2002) 1.11
Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem (2010) 1.09
Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation (2006) 1.09
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis (2013) 1.08
Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant (2001) 1.08
Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation (1997) 1.07
Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol (1996) 1.07
Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int (2008) 1.07
The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia (2006) 1.07
Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab (2006) 1.07
Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation (2006) 1.07
Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest (1996) 1.06
Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation (2007) 1.06
New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation (2005) 1.06
{beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab (2010) 1.04
Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant (2003) 1.04
Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant (2008) 1.04
Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet (2012) 1.03
Specific glucose-induced control of insulin receptor substrate-2 expression is mediated via Ca2+-dependent calcineurin/NFAT signaling in primary pancreatic islet β-cells. Diabetes (2011) 1.03
Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant (2005) 1.01
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant (2009) 1.00
(13) Diabetes care in the hospital, nursing home, and skilled nursing facility. Diabetes Care (2015) 0.99
Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab (2004) 0.99
Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation (2008) 0.98
Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation (1998) 0.98
Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant (2013) 0.97